Aimmune Therapeutics Europe

https://www.aimmune.com

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4–17 years of age. Aimmune plans to submit regulatory filings for marketing approval of AR101 in the United States and Europe based on data from the pivotal Phase 3 PALISADE clinical trial of AR101, which in 4–17-year-old subjects met its primary and key secondary endpoints, and additional ongoing and completed AR101 clinical trials. *

	Start	2016-11-04 existent
	Group	Nestlé (Group)
	Today	Aimmune Therapeutics Inc. (Nasdaq: AIMT)
	Industry	CODIT™ (Characterized Oral Desensitization ImmunoTherapy)
	Industry 2	antiallergic

	Region	London, Greater London
	Country	United Kingdom (GB)
	Street	344–354 Gray's Inn Road
	City	WC1X 8BP London
	Tel	+44-208-629-0240
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Aimmune Therapeutics, Inc.. (11/1/18). "Press Release: Aimmune Therapeutics to Participate in Upcoming Investor Conferences". Brisbane, CA.

		Record changed: 2023-07-10